Home » Stocks » Addex Therapeutics

Addex Therapeutics Ltd. (ADXN)

Stock Price: $12.46 USD 0.00 (0.00%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 409.29M
Revenue (ttm) 2.85M
Net Income (ttm) -14.78M
Shares Out 32.85M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $12.46
Previous Close $12.46
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 11.47 - 12.46
Day's Volume 0
52-Week Range 6.19 - 37.52

More Stats

Market Cap 409.29M
Enterprise Value 377.33M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 32.85M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.58
FCF / Share -1.79
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1,021
Short Ratio 0.00
Short % of Float n/a
Beta 1.34
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 143.70
PB Ratio 2.67
Revenue 2.85M
Operating Income -15.13M
Net Income -14.78M
Free Cash Flow -9.80M
Net Cash 31.96M
Net Cash / Share 0.97
Gross Margin 100.00%
Operating Margin -531.16%
Profit Margin -535.00%
FCF Margin -344.23%
ROA -29.38%
ROE -57.41%
ROIC 538.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions CHF.

Financial Overview

Year201920182017
Revenue2.766.04-
Revenue Growth-54.29%--
Gross Profit2.766.04-
Operating Income-14.67-2.08-3.73
Net Income-14.78-1.64-3.28
Shares Outstanding32.8532.85-
Earnings Per Share-0.56-0.07-0.25
Operating Cash Flow-9.481.75-2.14
Capital Expenditures-0.03-0.01-
Free Cash Flow-9.511.74-2.14
Cash & Equivalents31.5541.682.59
Total Debt0.55--
Net Cash / Debt31.0041.682.59
Assets33.0342.213.06
Liabilities7.502.971.72
Book Value25.5239.241.34
Numbers in millions CHF, except per-share numbers.

Company Profile

Company Details

Full Name Addex Therapeutics Ltd.
Country Switzerland
Employees 19
CEO Timothy Dyer

Stock Information

Ticker Symbol ADXN
Stock Exchange NASDAQ
Sector Health Technology
Industry Pharmaceuticals: Major
Unique Identifier NASDAQ: ADXN

Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.